Abstract
Objective: This study aimed to explore the correlation of serumATG5 levels with the disease risk, Th2/Th1 imbalance, symptoms and therapeutic outcomes of allergic rhinitis (AR) patients. Methods: Serum ATG5 levels in 160 AR patients, 30 disease controls and 30 healthy controls were measured by ELISA. AR patients received oral antihistamine, intranasal corticosteroid, leukotriene receptor antagonist monotherapy or their combination as needed for 4weeks. Results: AR patients had elevated ATG5 levels compared with disease controls and healthy controls (p<0.001). In AR patients, ATG5 levels were positively correlated with total nasal symptom scores, IL-4 levels and the IL-4/IFN-γ axis (all p<0.05); the reduction in the ATG5 level was positively related to the total nasal symptom score decline from week0 to week4 (p=0.038). Conclusion: Serum ATG5 levels have diagnostic and disease-monitoring value in AR management due to their relationship with Th2 cells and symptoms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
